ライフサイエンスコーパス: eye drop

1 before and after instillation of an emulsion eye drop.

2 ot that can be administered as a traditional eye drop.

3 ted eye, compared to brimonidine twice-daily eye drops.

4 e barriers compared to current treatment via eye drops.

5 henicol eye drops and 163 to receive placebo eye drops.

6 jection, intramuscular injection, or topical eye drops.

7 treated with dexamethasone (DEX) or control eye drops.

8 IOP for one month as an alternative to daily eye drops.

9 most patients elect to start treatment with eye drops.

10 P was 14.3 +/- 3.4 mmHg while on 1.5 +/- 0.8 eye drops.

11 , blood pressure, heart rate, mydriatic, and eye drops.

12 P was 12.2 +/- 2.2 mmHg while on 1.1 +/- 0.9 eye drops.

13 tervention group) or placebo (control group) eye drops.

14 efore and after the treatment with 0.05% CsA eye drops.

15 ffective and efficient delivery devices than eye drops.

16 hosts were challenged with OVA (Texas-Red+) eye drops.

17 ated with saline plus topical corticosteroid eye drops (0.5% loteprednol etabonate) 4 times daily for

18 e effect of giving this octamer (8mer) as an eye drop 1 hour before ocular infection with HSV-1 was i

19 Prednisolone acetate eye drops 1% 5 times daily for the first week after surg

20 nge of therapy regimen: Prednisolone acetate eye drops 1% hourly for the first postoperative week.

21 e acetate 1%, or ketorolac tromethamine 0.5% eye drops 4 times per day for 5 days commencing immediat

22 Patients applied aganirsen eye drops (86 mug/day/eye) or placebo twice daily for 90

23 The pharmacologic activity of SAR 1118 eye drops administered thrice daily for 2 months at 1% (

24 sulin levels and by examining the effects of eye drop administration in decapitated rats.

25 ejection is highest and when typical steroid eye drop administration requirements are particularly on

26 We assessed the effect of fluorouracil 1% eye drops after surgery on recurrence.

27 laucoma medication adherence, interest in an eye drop aid, and self-reported adherence (measured by t

28 12 of them were treated with 0.25 % atropine eye drop and another 12 served as a control group.

29 gned 163 children to receive chloramphenicol eye drops and 163 to receive placebo eye drops.

30 enced in using both Mydriasert and mydriatic eye drops and results from the current clinical study of

31 the bioavailability of drugs delivery using eye drops and suspensions.

32 received the gK 8mer or control peptides as eye drops and were then ocularly infected with HSV-1.

33 assay of CFX in pharmaceutical formulation (eye drops) and biological fluid (urine) by a significant

34 on-invasive ocular delivery methods, such as eye drops, and systemic delivery, have low bioavailabili

35 d that when Mydriasert substituted mydriatic eye drops, annual total costs decreased by 18% and annua

36 n the retina of normal rats 20 minutes after eye drop application (0.7 pg/microg; P < 0.00001).

37 sity of Washington who were experienced with eye drop application and were on a steady regimen of sel

38 At therapeutic doses, eye drop application of the dnG1 retroviral vector is sa

39 Insulin eye drops (approximately 15 microL: 0.75% porcine insuli

40 Additionally, these eye drops are often prescribed for daily use for 1 year

41 However, steroids delivered in eye drops are rapidly cleared from the surface of the ey

42 te 0.5 % (50/99, 51 %), and autologous serum eye drops (ASD; 48/97, 49 %).

43 underwent pupil dilation with 1% tropicamide eye drops at the baseline visit, before any laser or med

44 the use of Olopatadine 0.1% or cyclosporine eye drops before DALK (OR = 14.51, 95% CI = 1.43-147.23)

45 urther evaluation and consideration of early eye drop bottle exhaustion in glaucoma patients.

46 by this higher level (>/= 5 times yearly) of eye drop bottle exhaustion were more likely to have poor

47 main outcome measure was self-reported early eye drop bottle exhaustion.

48 eported any problem with early exhaustion of eye drop bottles, and this was associated with visual ac

49 s on daily basis was comparable with that by eye drops but with only 20% of drug dose, which suggeste

50 ration of G1 or G2 peptide as a prophylactic eye drop completely blocked HSV-1 spread in the mouse co

51 actively immunized mice challenged with OVA eye drops containing 1% anti-CCR7 antibody or isotype co

52 were challenged for 7 consecutive days with eye drops containing the allergens.

53 altered eyes were subsequently treated with eye drops containing: a retroviral vector bearing a dnG1

54 Nepafenac eye drops do not increase the IOP.

55 Glaucoma is commonly treated with daily eye-drop drugs, but adherence to treatment is often unsa

56 y allocated to receive 50% glucose or saline eye drops every 5 minutes for 60 minutes.

57 ong-term, non-invasive gel/microsphere (GMS) eye drop for glaucoma.

58 days later, received artificial tears or CsA eye drops for 6 weeks.

59 In vivo delivery of GFX in a dendrimer eye drop formulation was studied in New Zealand White ra

60 retinal angiogenesis when administered in an eye-drop formulation.

61 ded wear contact lenses was then compared to eye drops in beagle dogs that suffer from spontaneous gl

62 herapeutic efficacy to topically applied Dex eye drops in experimental mouse dry eye model, and these

63 needed ranibizumab administered with placebo eye drops in maintaining BCVA (estimated BCVA gains of 0

64 Daily pazopanib eye drops in neovascular AMD subjects did not result in

65 insert was compared with twice-daily timolol eye drops in patients with open-angle glaucoma (OAG) or

66 he efficacy of N-acetylcysteine amide (NACA) eye drops in reversing the cataract formation induced by

67 -102 (brimapitide) compared to dexamethasone eye drops in the treatment of postoperative ocular infla

68 ular surgery is noninferior to dexamethasone eye drops in the treatment of postoperative ocular infla

69 to the effectiveness of prostaglandin analog eye drops in treating primary open-angle glaucoma, publi

70 To replace the need for eye drops, in this study we tested the hypothesis that I

71 In addition, SST eye drops inhibited glutamate accumulation in the retina

72 s administered for 52 weeks included placebo eye drops instilled 4 times daily (n=73); pazopanib 5 mg

73 XG-102 900 mug, or placebo) was followed by eye drops instilled 4 times per day for 21 days with pla

74 Prolonged use of corticosteroid eye drops is a major risk factor for the occurrence of p

75 proper procedure for application of topical eye drops is stressed.

76 n, gentamicin and vancomycin or levofloxacin eye drops leading to enucleation in one case.

77 Our study demonstrates that corticosteroid eye drops mitigate the acute adverse effects of an exper

78 despite its higher unit cost than mydriatic eye drops, Mydriasert resulted in overall savings in hea

79 Tg-MYOC(Y437H) mice were treated with PBA eye drops (n = 10) or sterile PBS (n = 8) twice daily fo

80 A single eye drop of 10(-5) M naltrexone (NTX), 10(-5) M [Met(5)]

81 Eye drops of aganirsen, an antisense oligonucleotide pre

82 ects of systemic and topical administration (eye drops) of GLP-1R agonists in db/db mice; and 3) to e

83 icate that periodic induction, via use of an eye drop, of AAV-mediated secretion of MMP-3 into AH cou

84 l treatment was administered by using 4% CsA eye drops or vehicle (castor oil) four times daily for 1

85 llitus (STZ-DM) were treated with either SST eye drops or vehicle for 15 days.

86 to either Group 1, who received timolol 0.5% eye drops, or Group 2, who received artificial tears for

87 Treatment with SST eye drops prevented ERG abnormalities, glial activation,

88 d prevalence of early exhaustion of glaucoma eye drops prior to a scheduled refill, and associated ri

89 (8-11 times per year) or "always" ran out of eye drops prior to a scheduled refill.

90 ne 0.1% or any concentration of cyclosporine eye drops prior to DALK.

91 by poor patient adherence to the prescribed eye drop regimen.

92 ation, and preferable to difficult and toxic eye-drop regimens.Immunochromatographic assay is an effe

93 printed lenses than non-imprinted lenses and eye drops, respectively.

94 , 0.44 [95% CI, 0.24 to 0.60]; P < .001) and eye drops (rho, 0.47 [95% CI, 0.27 to 0.62]; P < .001).

95 t population, or to those inexperienced with eye drop self-administration.

96 Instillation of an emulsion eye drop significantly increased the thickness of the li

97 f corneal angiogenesis showed that aganirsen eye drops significantly inhibited corneal neovasculariza

98 SAR 1118 eye drops significantly reduced leukostasis and blood-re

99 y applied towards the detection of GSH in an eye drop solution.

100 s in the previous study, the identity of all eye drop solutions was masked.

101 We tested the hypothesis that topical (eye drop) SRPK1-selective inhibitors could be generated

102 pically administered prodrug delivered as an eye drop that is readily converted to the active compoun

103 d with artificial tear and anti-inflammatory eye drops that are generally administered several times

104 Glaucoma management through eye drops that reduce the intraocular pressure (IOP) has

105 bitors could be a potentially novel topical (eye drop) therapeutic for wet AMD.

106 h TM-implant contact lenses in comparison to eye drop therapy.

107 acebo (n = 22) was preoperatively applied as eye drops to 1 eye in patients scheduled for cataract su

108 sulin levels, and the application of insulin eye drops to decapitated rats still resulted in the accu

109 t insert may provide an alternative to daily eye drops to improve adherence, consistency of delivery,

110 riasert compared with conventional mydriatic eye drops to induce pupil dilation prior to cataract sur

111 In addition, for all eye drop treatment groups, open-label ranibizumab was ad

112 Either eye drop treatment of 1% apoEdp topically 4 times a day

113 Topical eye drop treatment with dexamethasone (P < 0.01) or cycl

114 twice a day topically applied dexamethasone eye drop treatment.

115 riasis with Mydriasert compared to mydriatic eye drops (tropicamide [1%] plus phenylephrine [10%]).

116 ceive SAR 1118 (0.1%, 1.0%, 5.0%) or placebo eye drops twice daily for 84 days.

117 3%), congestive heart failure (78%), steroid eye drop use (65%), and the non-emergency vaccination of

118 perties of said drugs, which included liquid eye drops, viscous cold syrup solution, ointment cream,

119 N-acetylcysteine amide eye drops were administered beginning on week 3 until th

120 Nepafenac (0.1%) eye drops were instilled 3 times a day in the eye that r

121 ery, with or without the use of IOP-lowering eye drops, were 70%, 72%, 60%, and 44%, for achievement

122 Glaucoma is commonly treated using eye drops, which is highly inefficient due to rapid clea

123 cal corticosteroids: prednisolone acetate 1% eye drops with or without dexamethasone 0.1% eye ointmen

124 compare the effectiveness of chloramphenicol eye drops with placebo in children with infective conjun

125 which allows easy application in the form of eye drops without any vision interference.

126 greater than non-imprinted lenses and 0.035% eye drops (Zaditor(R)), respectively.